Sort   by:  
 Page size 
ModelsKemmer2022 - Disentangling ERBB Signaling in Breast Cancer Subtypes – a Model-Based Analysis
This is a dynamic pathway model capturing ERBB receptor signaling as well as downstream MAPK and PI3K signaling pathways. The effect of different growth factors and drugs on the formation of active receptor dimers is explicitly included. The model was established and calibrated on time-resolved data...
2022-05-30 | MODEL2205030001 | BioModels
Models,MultiomicsSKBR3 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2703 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2697 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Long-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2698 | Cell Collective
Models,MultiomicsBT474 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2699 | Cell Collective
Models,MultiomicsHCC1954 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2700 | Cell Collective
Models,MultiomicsSKBR3 Breast Cell Line Short-term ErbB Network
Background Despite promising progress in targeted breast cancer therapy, drug resistance remains challenging. The monoclonal antibody drugs trastuzumab and pertuzumab as well as the small molecule inhibitor erlotinib were designed to prevent ErbB-2 and ErbB-1 receptor induced deregulated protein sig...
2701 | Cell Collective
Sort   by:  
 Page size